A functional reference map of the RNF8 interactome in cancer

Chuanyang Liu†, Jingyu Kuang†*, Yuxuan Wang1, Ting Duan2, Lu Min1, Chenyu Lu1, Tianyi Zhang1, Ruifen Chen3, Ying Wu4 and Lingyun Zhu1*

Abstract

Background: RNF8 is an E3 ligase identified as a critical DNA damage-responsive protein. Recently, multiple reports have shown that RNF8 could be used as an important therapeutic target for cancer chemo/radiotherapy. However, the understanding of RNF8 remains limited due to the lack of its interactome reference map and comprehensive analysis of RNF8 in diverse cancers, which underscores the need to map the interactome of RNF8 via high-throughput methods.

Results: A two-way identification method based on LC–MS was designed for the identification of the RNF8 interactome with high-specificity. By in silico analysis and in vitro validation, we identified a new reference map of the RNF8 interactome network containing many new targets, such as YBX1, DNMT1, and HDCA1, new biological functions and the gene-disease associations of RNF8. Our results revealed a close relationship between RNF8 and neurodegenerative diseases or tumor-infiltrating immune cells using bulk RNA-seq and scRNA-seq datasets. As a proof of concept of our interactome map, we validated the direct binding between RNF8 and YBX1 and showed that RNF8 catalyzed the ubiquitination of YBX1. These results demonstrated that RNF8 might be a crucial regulator of YBX1.

Conclusions: Our work provides a unique framework for researchers and clinicians who seek to better explore or understand RNF8-regulated biological functions in cancers. This study will hopefully facilitate the rational design and further development of anti-RNF8 therapy in cancers.

Keywords: Pancancer analysis, RNF8, Interactome, YBX1, Ubiquitination

†Chuanyang Liu and Jingyu Kuang have contributed equally to this work
*Correspondence: kuangkuangyu@126.com; lingyunzhu@nudt.edu.cn
1 Department of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha 410073, Hunan, China
Full list of author information is available at the end of the article
Background

RNF8 (UniProtKB Accession Number: O76064) is a 484-amino-acid E3 ligase that consists of two conserved domains [1, 2]: an N-terminal forkhead-associated (FHA) domain, a phosphopeptide recognition domain found in many regulatory proteins, and C-terminal Really Interesting New Gene (RING) domain that catalyze the formation of ubiquitin chains on substrates, which is responsible for its E3 ubiquitin ligase activity [3]. Together with E1 ubiquitin-activating enzyme and E2 ubiquitin-conjugating enzymes such as Ubc13, RNF8 is capable of catalyzing the assembly of K63-/K48-linked polyubiquitin chains on its substrates and therefore contributes to their nucleic translocation and protein degradation [4]. RNF8 was originally identified as a critical DNA damage-responsive protein and contributes importantly to DNA double-strand repair (DSB) repair. In response to DSBs induced by stimuli such as ionizing radiation and reactive oxygen species, the C-terminus of histone H2A variant (H2AX) is phosphorylated and interacts with MDC1, which leads to the recruitment of RNF8 to the sites of DSBs via its FHA domain and therefore mediates the formation of K63-linked polyubiquitin chains on histones [3, 5]. This ubiquitin signaling promotes the subsequent recruitment of multiple DNA damage repair factors such as 53BP1 and BRCA1, thereby enabling homologous directed repair. In addition, RNF8 targets nonhomologous end joining factor KU (KU70/KU80) for K48-linked ubiquitination [6], and promotes efficient DSB damage repair by decreasing the proapoptotic activity of p53 through regulating Tip60 protein activity [7].

In addition to DNA double-strand break repair, RNF8 has also been found to play important roles in various biological processes [7, 8], such as chromatin remodeling [9], inflammation signaling [10], spermatogenesis [1, 11], telomere maintenance, and end protection [12], by interacting with divergent target proteins. Therefore, RNF8 can be partly recognized as the “Guardian” of our cells. However, even though many gain-of-function and loss-of-function studies have elucidated the distinct function of RNF8 in divergent physiological statuses, the general function of RNF8 has been poorly discussed due to the lack of high-throughput identification of
its interactome (or substrates), which underscores the need to comprehensively reveal the molecular mechanism underlying this crucial biological process.

Recently, several findings revealed oncogenic potential might be the other side of the coin of RNF8 functions. Studies have shown that RNF8 is also involved in many cancer-associated biological processes such as tumorigenesis and cancer metastasis. Kuang et al. found that RNF8 promotes breast cancer epithelial–mesenchymal transition (EMT), an essential process in cancer metastasis that facilitates the infiltration of tumor cells into surrounding tissues [13, 14], via inactivation of GSK-3β and activation of β-catenin signaling [3]. A similar breast cancer-promoting rule of RNF8 was also demonstrated by Lee et al., which showed that RNF8 facilitates cancer chemoresistance and progression through activation of Twist, a transcriptional control factor of the epithelial–mesenchymal transition, by RNF8-mediated K63-linked polyubiquitin [4, 15]. The critical roles of RNF8 in lung cancer tumorigenesis [2, 16], bladder cancer radiosensitivity [17], hepatocellular carcinoma growth, and metastasis [18] were also revealed recently. In our previous study, we also revealed that RNF8 promoted epithelial–mesenchymal transition in lung cancer [2]. Despite the emerging understanding of the biological function of RNF8 in cancers, the underlying molecular mechanism of how RNF8 and its interactome network regulate divergent pathways and phenotypes is needed.

Here, we integrated liquid chromatography-tandem mass spectrometry (LC–MS) and massive bioinformatic analyses to profile the interactome and overall functions of RNF8. The aim of this study was to systematically reveal the potential molecular mechanism underlying RNF8-associated biological processes and establish a comprehensive RNF8-interactome regulation network with high specificity, which might reinforce the association between RNF8 and its regulated physiological and pathological processes. These findings will provide a reference map for exploring, understanding and analyzing RNF8-related biological processes and clinical value.

Results

Pancancer expression pattern and prognostic value of RNF8

First, to reveal the expression pattern in different cancer types, the expression of RNF8 was analyzed in pancancer tissues and associated normal tissues. The results showed that the expression of RNF8 is significantly upregulated in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ) and uterine corpus endometrial carcinoma (UCEC). In addition, significant downregulation of RNF8 was observed in kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD) and thyroid carcinoma (THCA) (Fig. 1A, Additional file 1: Fig. S1A and Additional file 1: Fig. S1B). Then, Kaplan–Meier analysis was performed to assess the potential prognostic value of RNF8 in cancers, and the results are shown in Fig. 1B.

Integrating the aberrant expression pattern with the prognostic value, we identified nine cancer types that were strongly associated with tumorigenesis and prognosis: LIHC, STAD, BRCA, CHOL, HNSC, LUAD, OV, KIRC and TCGT. In LICH, STAD, BRCA, CHOL and HNSC (Group 1), elevated expression of RNF8 was observed in tumor tissues and was related to poor prognosis. In LUAD, OV, KIRC and TCGT (Group 2), the trend was reversed. These results indicated that, among these nine cancers, RNF8 expression might be a crucial factor for tumorigenesis and cancer progression. Therefore, the correlation between RNF8 expression and clinical parameters of cancers was further analyzed, and the results showed that RNF8 was significantly associated with parameters such as sample type, pathologic_t and neoplasm grade in Group 1 (Fig. 1D). In breast cancer, RNF8 is associated with many key clinical parameters such as estrogen receptor status, IHC positive cells, and progesterone receptor. Therefore, a further elaborate analysis was performed and is shown in Additional file 1: Fig. S1C and Additional file 2: Fig. S2. In Group 2 cancers, the expression of RNF8 was associated with distinct clinical parameters when compared to Group 1. Taken together, these results further demonstrated the connection between RNF8 and clinical parameters in different cancers.

Identification of the RNF8 interactome via LC–MS

The distinct and critical roles of RNF8 in tumorigenesis, cancer progression and resistance to chemotherapy are found both in our results and many previous reports [2, 3, 19–21]. We are quite curious about how RNF8 regulates abundant and different biological processes such as breast cancer metastasis [3, 19], lung cancer tumorigenesis [16], DNA double-strand break repair [7, 8], chromatin remodeling [9] and spermatogenesis [1, 11]. Considering that the functional basis of RNF8 is basically to interact with its targets, we thought identifying its direct targets and interacting proteins is more useful to understand how RNF8 participates in various biological processes, such as LC–MS, compared to other high-throughput omics.
Therefore, we designed a high-specificity RNF8-interactome identification method by integrating anti-RNF8-based IP with anti-Flag (+ anti-HA)-based IP (Fig. 1E). Briefly, based on the transfection of the Flag-HA (FH-tag)-RNF8 plasmid, a co-IP assay using anti-Flag-M2-beads was performed to obtain the Flag-HA-RNF8 protein and its interacting proteins. To further improve the specificity of the IP assay, another round of co-IP using anti-HA-beads was performed using elution from the previous step, to obtain FH-RNF8-interacting proteins. SDS–PAGE and silver staining were performed to verify the expression of RNF8 and specific bands that could be sent to liquid–mass spectrometry (LC–MS) for analysis (Fig. 1F). In addition, another co-IP assay using an anti-RNF8 antibody was also performed to minimize the potential nonspecific interacting protein signal.
Two RNF8 interactomes (893 proteins in the anti-FH group and 551 proteins in the anti-RNF8 group) were acquired via LC–MS (Fig. 2A, Additional file 15: Table S1). The protein IDs in the two datasets were converted to Entrez IDs, and the intersection of these two protein sets was integrated and visualized. Finally, 218 overlapping proteins, including YBX1 and PCNA were obtained (Fig. 2C and Additional file 15: Table S1).

Functional enrichment of the RNF8 interactome

To further understand the functional and regulatory patterns of the RNF8 interactome at the cellular level, we performed GO annotation and KEGG pathway enrichment using the functional enrichment package clusterProfiler [22]. As shown in Fig. 2B, terms such as cell adhesion molecular binding, translation factor activity, RNA binding, and structural constituent of cytoskeleton were enriched in GO molecular functions (MFs). Regarding GO biological processes (BPs), these 218 proteins were mainly enriched in epidermal cell differentiation, keratinocyte differentiation, neutrophil-mediated immunity, neutrophil activation, etc. (Fig. 2C). Regarding cellular components (CCs), the proteins were significantly enriched in the cell-substrate junction, focal adhesion, cytoplasmic vesicle lumen, and intermediate filament cytoskeleton (Fig. 2D). Furthermore, neurodegenerative diseases such as the Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis were enriched by the KEGG pathway (Fig. 2E). Additionally, protein processing in the endoplasmic reticulum, DNA replication and repair, coronavirus disease (COVID-19), and the estrogen signaling pathway were enriched. For Wikipathway enrichment, the most enriched terms were cytoplasmic ribosomal proteins, translational factors, glycolysis and gluconeogenesis, DNA replication, and the parkin-ubiquitin proteasomal system pathway (Fig. 2F). These results indicate that there might be unrecognized associations between RNF8 and these processes.

Other important biological pathways were also shown with identified target proteins (Table 1). To our surprise, apart from DNA repair, the p53 signaling pathway, the cell cycle, chromatin organization and...
the TNF-α pathway, which have been partly reported in RNF8-related studies [23], many of the identified targets have not yet been validated. In addition, the correlation between RNF8 and many of the identified pathways such as oncogenic MAPK pathways, epigenetic regulation, TGF-beta receptor, sumoylation, integumentary system disease, keratosis, skin disease (Additional file 3: Fig. S3A and B), and most of the identified target proteins, has not been reported, which underscores deeper exploration and more mechanistic insights toward RNF8.

### Construction and clustering of the PPI network

To further elucidate the potential interactions among the 218 overlapping proteins, a protein–protein network was constructed utilizing the Metascape database [22] with the following databases: STRING6, BioGrid7, OmniPath8 and InWeb_IM9. Only physical interactions in STRING (physical score > 0.132) and BioGrid were used. The resultant network contains the subset of proteins that form physical interactions with at least one other member in the list. Then, the Molecular Complex Detection (MCODE) algorithm10 was applied to identify densely connected network components (Additional file 3: Fig. S3A and B), and BioGrid were used. The resultant network contains the subset of proteins that form physical interactions with at least one other member in the list. Then, the Molecular Complex Detection (MCODE) algorithm10 was applied to identify densely connected network components (Additional file 3: Fig. S3A and B), which is biased in favor of showing the characteristics of the network (Additional file 3: Fig. S4A–F).

Further functional analysis showed the direct relationship between identified proteins and biological processes such as proteasome, nucleotide excision repair (MCODE Cluster 1), target ribosome, RNA transport (MCODE Cluster 2), pathogenic Escherichia coli infection, phagesome (MCODE Cluster 3), spliceosome, Alzheimer’s disease (MCODE Cluster 4) and oocyte meiosis (MCODE Cluster 5). These results further reinforced the relationship between RNF8’s target proteins in these clusters and corresponding diseases or biological processes, which might also be the unrecognized functions of RNF8 (Additional file 5: Fig. S5).

### The correlation between RNF8 and biological pathways in cancers

To further reduce the bias in the identification of the RNF8 functional profile, another round of functional profiling using large-sample high-throughput sequencing data was performed (Fig. 3A). Based on pancancer-normalized mRNA abundance data of nine cancers, we trisected samples (Additional file 6: Fig. S6J–R), and divided them into an RNF8 high-expression group and an RNF8-low expression group in different cancer types. Using differential gene expression analysis between the two groups (Additional file 6: Fig. S6A–I), we identified RNF8 functions in a novel abundance-based way.

Consistent with previous findings, gene ontology and KEGG enrichment analyses showed that the upregulated genes in Group 1 cancers were enriched in cell cycle and spermatogenesis (Fig. 4A–C, Additional file 7: Fig. S7A), while the downregulated genes were enriched in cytochrome P450 (metabolism of drug/xenobiotics), hormone metabolic process, downregulation of KRAS signaling and estrogen response (Fig. 4D–F, Additional file 7: Fig. S7B). In Group 2 cancers, however, the results showed a different picture, and the terms in which upregulated genes were enriched in did not show a common pattern (Additional file 8: Fig.}

### Table 1 The enriched key pathways and identified targets

| Pathway                      | Members                                                                 |
|------------------------------|-------------------------------------------------------------------------|
| Epigenetic regulation of gene expression | HDAC1; SIRT1; UBTIF; CHD4; GTF2H3; DNMT1; RBBP4; POLR2E; POLR1A; DEK; MBD3; MYBBP1A; GTF2H4; MTA2 |
| Chromatin organization       | HDAC1; KDM1A; WDR5; RUVBL1; CHD4; HCF1C; MTA2; NFKB2; RUVBL2; PRMT5; MOF4L2; UTR77; KDM5A |
| DNA repair                   | PCNA; POLR2E; DBD1; TP53; RAD51; GTF2H3; TCEA1; POLR2A; COP55; APEX1; CDK2; PARP1; TP53BP1; ACTL6A; POLR2C; ASCC3; RUVBL1; GTF2H4; XRC5; XRC6 |
| TNFalpha                     | HDAC1; TXN; DDX3X; LRRPRC; POLR1A; MCM7; YWHAB; MAPK1; ACTL6A; CDK9; CCNT1; FLNA; PSMC2; NFKB2 |
| Oncogenic MAPK signaling     | PHB; MACF1; FXR1; MAPK1; SN1; YWHAB; MEF2C; PPP2CA |
| TGF-beta_Receptor           | HDAC1; DAXX; TP53; COP55; MEF2C; CDK2; MAPK1; EWSR1 |
| C-MYC pathway               | PPP2CA; RUVBL1; ACTL6A; RUVBL2 |
| SUMOylation                  | PCNA; TP53; NUP98; PARP1; HNRPK; TP53BP1; HNRPNC; RNF2 |
| p53 signaling pathway       | PCNA; CDK2; TP53 |
| mRNA splicing               | SRSF1; SRSF2; POLR2E; POLR2A; POLR2C; YBX1; PRPF6… |
| Cell cycle                   | HDAC1; AHCFT1; RUVBL1; TP53; RUVBL2; PPP2CA; NUP98; RBBP4; MCM7; PCNA; CDK2; MAPK1; MCM3; TERF21P; YWHAB; TP53BP1; NPM1 |
S8A–D). The downregulated genes were enriched in cytokine-cytokine receptor interactions, upregulation of KRAS signaling, etc. (Additional file 8: Fig. S8E–H). In addition, batch gene set enrichment analysis showed that RNF8 was enriched in terms such as the MAPK signaling pathway, focal adhesion, and transcriptional misregulation in cancer.

**The correlation between RNF8 and biological pathways in cancers**

To our surprise, we observed that immune cell-related terms such as natural killer cell mediated cytotoxicity (Fig. 3B, C), inflammatory response (Fig. 4F) and T-cell activation (Additional file 8: Fig. S8F and H) were enriched both in GSEA and multiple previous enrichment.
analyses, which attracted our interest. Multiple previous studies have demonstrated that RNF8 regulates the progression and metastasis of cancer cells in different cancers [2–4]. Whether RNF8 regulates tumor-infiltrating immune cells and whether this regulation affects cancer status, such as progression or metastasis are unknown.

To explore the function of RNF8 in the tumor microenvironment (TME), a six-tumor microenvironment algorithm was used to assess the abundance of cell types in nine cancers. The results showed that the correlation between RNF8 and tumor infiltration varied in different cancers (Fig. 3D). The expression-based method was utilized for further validation (Fig. 3E). In the RNF8 high expression group, significant increase in naïve B cells was observed in TGCT, as well as decreased memory B cells in HNSC, upregulated T follicular helper cells in LIHC, downregulated Tregs in HNSC and KIRC, and upregulated M1 macrophages in BRCA and STAD.

To further validate these findings, ten TNBC breast cancer scRNA-seq datasets were collected and analyzed (Fig. 3F). The results showed that RNF8 mean expression was positively correlated with the percentage of macrophages, monocytes (Fig. 3G, H) and NK cells (Fig. 5C) among nontumorous cells, which is consistent with previous findings. In other identified immune cells, there were no significant correlations (Fig. 5).

Taken together, these findings revealed the potential correlation between RNF8 and tumor-infiltrating immune cells, which might provide new insight into RNF8’s functional heterogeneity in divergent cancers.

Searching for potential RNF8-interacting proteins

As another way to find potential RNF8-interacting proteins, five well-known protein–protein interaction databases and prediction tools, STRING, GeneMANIA, InBio_Discover, BioGRID, and HitPredict, were screened and analyzed. As shown in Additional file 9: Fig. S9, 11 proteins appeared in at least four datasets. These proteins might be promising interacting proteins of RNF8 (Additional file 16: Table S2). Pancancer survival analysis found that these proteins, together with identified target proteins, were negatively correlated with patient survival (Additional file 10: Fig. S10 in ACC, LIHC, LUAD, SARC, showing their potential to be biomarkers for prognosis. However, when we compared these proteins with the protein list acquired by LC–MS, only a few proteins (7 in 218) were in the union of all five protein sets, which is quite surprising.
Validation of RNF8-YBX1 interaction and functions: a case of proof-of-concept

To confirm the LC–MS-identified RNF8 interactome, we chose YBX1, a critical regulator of transcription and translation that is widely recognized as an oncogenic driver in several solid tumors such as breast cancer [24, 25], which was only identified by LC–MS and not in 5 PPI databases (Fig. 6A) as the proof-of-concept target.

Three co-IP assays were designed to verify the direct interaction between RNF8 and YBX1 (Fig. 6B). As shown in Fig. 3C, the RNF8 band was observed both in the input and elution of HEK 293T cells transfected with pcDNA3.1-FH-RNF8, while in elution, YBX1 was only observed in cells transfected with pcDNA3.1-FH-RNF8, which demonstrated the direct interaction between RNF8 and YBX1. Co-IP using anti-RNF8 antibodies to pull down the endogenous RNF8 complexes showed similar results (Fig. 6D). YBX1 also pulled down RNF8 protein using anti-Flag-M2 beads (Fig. 6E), further demonstrating the direct interaction between RNF8 and YBX1.

The classic function of RNF8 is to catalyze the ubiquitination of substrates and lead to their degradation, activation, or other alterations [12, 16, 26]. To further demonstrate the mechanism underlying the interaction between RNF8 and YBX1, the ubiquitination status of YBX1 in RNF8 overexpressing or RNF8-C406S (loss-of-function mutant, attenuating the activity of catalyzing the formation of the polyubiquitin chain to substrates) cells was assessed. The results showed that overexpression of RNF8 elevated the ubiquitination of YBX1, while the introduction of the C406S mutation to RNF8 reversed the ubiquitination status of YBX1. These results further prove the interactions between RNF8 and YBX1 and demonstrate that this interaction might regulate the ubiquitination of YBX1 (Fig. 6F).

Discussion

RNF8 is a 484-amino-acid E3 ligase located on chromosome 6p21.3 [1]. As demonstrated previously, the biological function of RNF8 largely originates from its two conserved domains: the FHA domain in the N-terminal, which binds to the phosphopeptide motif, and the RING domain in the C-terminal, which catalyzes the formation of the polyubiquitin chain [16]. As an E3 ligase, RNF8 has been shown to promote the formation of K63-, K48-, and K11-linked polyubiquitin chains when coupled with E2s such as UBC13, UBCH8, UbcH6, UBE2E3, and UBE2S, respectively. This ubiquitination of RNF8-interacting targets contributes to their nuclear translocation, activation,
Fig. 6  In vitro validation of the interaction between RNF8 and YBX1. A The intersection of RNF8 interactome by LC–MS and potential RNF8-interacting proteins acquired using five online tools. B Schematic diagram of Co-IP. C HEK-293T cells were transfected with pcDNA3.1 (control) or pcDNA3.1-FH-RNF8 and harvested after 48 h of transfection. HEK-293T cell lysates were incubated with HA-Sepharose beads, and the bound proteins were analyzed via western bolting with anti-RNF8, anti-HA, and anti-YBX1 antibodies. D We harvested MDA-MB-231 cells, then the lysates were co-immunoprecipitated with anti-RNF8 antibody or normal mouse IgG (control), and the elution protein complexes were analyzed by western blotting with anti-RNF8 and anti-YBX1 antibodies. E HEK-293T cells were transfected with TG006 or TG006-RNF8 with pcDNA3.1-FH-YBX1. At 48 h post-transfection, the cells were harvested and co-immunoprecipitated with anti-Flag-M2 agarose beads, and the YBX1 protein complexes were analyzed by western blotting with anti-YBX1 and anti-RNF8 antibodies. F HEK-293T cells were serially transfected with the corresponding plasmid. At 72 h post-transfection, the cells were harvested and communoprecipitated with anti-Flag-M2 agarose beads, and the YBX1 protein complexes were analyzed by western blotting with anti-Myc (Ub), anti-YBX1, and anti-RNF8 antibodies.
protein degradation, etc. [6, 27]. Based on these functions, RNF8 plays important roles in various biological processes, such as the DNA damage response, telomere protection, cell cycle control, and transcriptional regulation [5]. However, it is quite confusing that RNF8 seems to have two roles. One is that RNF8 acts as a “Guardian” of our cell; it helps transduce DNA damage signals and initiate DSB repair upon DNA damage, maintain genomic stability and participate in spermatogenesis [12]. Downmodulation of RNF8 also enhances cancer cell radiosensitivity [28]. Another role of RNF8 is to promote lung cancer tumorigenesis and chemoresistance [2, 21] and to promote breast cancer metastasis [3], similar to a “Villain.” In light of the structure of RNF8 and the way RNF8 functions, we utilized LC–MS to identify its direct targets and interacting proteins to understand how RNF8 participates in distinct biological processes.

By integrating anti-RNF8-based IP with anti-Flag(+ anti-HA)-based IP, we identified the RNF8 interactome with high specificity. Our study provides a comprehensive reference map for RNF8 functions and reveals many new potential functions of RNF8. In our results, some of the RNF8-target pairs were demonstrated in previous reports, such as RNF8-UBC [29], while most of the RNF8-target pairs were not established previously. Given the massive studies presented recently about RNF8 biological functions and potential therapeutic applications, the identification of the RNF8 interactome surely would provide substantial evidence and instructions for RNF8-related mechanistic and functional studies.

As a proof of concept, we examined the RNF8-YBX1 interaction to validate our interactome identification in vitro. YBX1 is a transcription factor that has been demonstrated to participate in the spliceosome, apoptosis, translation, cell proliferation, and tumor progression [30, 31]. Recently, YBX1 has attracted much attention. Gandhi et al. showed that lincNMR regulated tumor cell proliferation through a YBX1-RRM2-TYMS-TK1 axis governing nucleotide metabolism [32]. In addition, Goodarzi et al. found that YBX1 stabilized pro-oncogenic transcripts and enhanced cancer cell metastasis under hypoxia [33]. In our study, we demonstrated the direct interaction between RNF8 and YBX1 and found that RNF8 promotes the ubiquitination of YBX1, which provides a novel molecular mechanism underlying YBX1-related biological processes. How RNF8-mediated YBX1 ubiquitination is involved in spliceosome and tumorigenesis needs to be explored in the future.

As shown in Table 1, our results identified for the first time the direct interaction between “Genome Guardian” RNF8 and key genes in epigenetic regulation. Previous reports showed that RNF8-dependent ubiquitination of histone H2A during meiosis establishes active epigenetic modifications [34]; however, how RNF8 regulates epigenetic modification remains largely unknown. As shown in Table 1, our results suggest that RNF8 might be a potential regulator of DNMT1, a key methyltransferase that maintains the methylation status after DNA synthesis and is associated with many important biological processes, such as early embryo implantation and tumorigenesis, via direct interaction. In addition, HDCA1, a deacetylase that inactivates the expression of neuronal genes in nonnervous tissues and is implicated in axonal alteration and degeneration of the cell [35], was identified as the target of RNF8. Adam et al. showed that RNF8-dependent polyubiquitination is required for the establishment of H3K27 acetylation. RNF8 was also reported to play a role in suppressing synapse formation [29] and neuron degeneration [36], but the clear mechanism underlying these physiological processes is poorly understood. Our findings might therefore provide new clues and evidence for these biological processes.

RNF8 is regarded as a DNA damage signal transducer. Upon DNA damage, the Mre11-Rad50-Nbs1 (MRN) complex senses the damage and recruits Ataxia telangiectasia mutated (ATM) to damage sites. ATM and ATR phosphorylated histone H2AX (referred to as γH2AX), and MDC1. RNF8 is then recruited to the DNA double-strand break site through FHA domain-mediated interaction with MDC1 [37, 38] and stabilizes JMJD1C demethylase, demethylating MDC1 at K45, which promotes MDC1 association with RNF8 [39]. RNF8 then couples with Ubc13, DYRK2 and L3MBTL2 to catalyze the formation of K63-linked polyubiquitin chains on many chromatin substrates, including histones H2A, H2AX, and H1 [40, 41], which results in the recruitment of DNA repair proteins, including 53BP1, BRCA1, and RAD51, to facilitate NHEJ or HR repair. RNF8 also regulates the abundance of the nonhomologous end-joining (NHEJ) repair proteins KU80 and JM2A by catalyzing K48-linked polyubiquitination at sites of DNA damage and it promotes efficient DSB damage repair by decreasing the proapoptotic activity of p53 through regulating Tip60 protein activity [40]. Our results showed that RNF8 might regulate DNA repair via multiple targets such as PCNA, TP53, RAD51, and CDK2. Some of the targets are consistent with numerous reports; for example, Li demonstrated that PCNA is a target of RNF8 and is monoubiquitinated by it. However, most of the other targets and the function of RNF8-target axes have yet to be explored.

Although preliminary, we provide evidence demonstrating that RNF8 might be involved in many biological pathways. To reveal the common function of RNF8 on a larger scale, integrated bioinformatics analysis and
network analysis were performed. Interestingly, in our KEGG enrichment analysis, we noticed is that RNF8 was involved in many neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (Fig. 2D). The relationship between RNF8 and these diseases might be a new area that needs to be further explored. As shown in Siwei’s study, RNF8 deficiency results in neurodegeneration in mice [36], but how RNF8 regulates these processes and exactly how RNF8 regulates neurodegenerative diseases still need to be further explored and discussed based on the identified interactome. In addition, the role of RNF8 in immunology-related processes such as neutrophil-mediated immunity and neutrophil activation, and whether these connections affect the role of RNF8 in cancer tissues have not been discussed and require further exploration. The spliceosome is another item that is enriched in both the MCODE and KEGG pathways. Many of our results show a strong connection between RNF8 and the mRNA spliceosome. Whether RNF8 regulates spliceosome and whether the regulation occurs via YBX1 or other identified targets require further experimental validation.

We noticed that the role of RNF8 in tumorigenesis, metastasis, and chemoresistance has been increasingly reported in many cancers recently. In breast cancer, RNF8 promotes cancer progression and metastasis through Twist activation, and RNF8-mediated epithelial–mesenchymal transition is also regulated by multiple miRNAs such as miR-622 and miR-214, which is consistent with our enrichment analysis results showing that the RNF8-interactome might participate in cadherin binding and cell adhesion. With multiple newly identified RNF8 targets, our identified interactome might be an alternative mechanism underlying these RNF8-regulated biological processes [4, 19, 42]. In hepatocellular carcinoma, Trabid inhibits cancer growth and metastasis by cleaving RNF8-induced K63-linked ubiquitination of Twist [18]. RNF8 also promotes tumorigenesis in lung cancer [16], and silencing RNF8 sensitized bladder cancer to radiotherapy [17]. Our results showed that RNF8 might participate in metabolic reprogramming in colon cancer and clear cell renal cell carcinoma. Ling et al. showed that RNF8 can induce β-catenin-mediated c-Myc expression and thus promote colon cancer proliferation, which is consistent with our findings. Additionally, our identification of RNF8-interacting ENO1, LDH1, PKM, PYCR, and MDH2 might provide other mechanisms underlying RNF8-regulated colon cancer progression.

In addition, our functional analysis of RNF8 in different cancers implied that RNF8 might be associated with the function of immune cells, these data quickly attracted our interest. As discussed above, many efforts have been made to discover how RNF8 regulates cancer progression, metastasis, and prognosis, while in view of tumor microenvironment, whether RNF8 influences the physiological status of tumor-infiltrating immune cells, a class of immune cells that play critical roles in cancer progression and are closely related to clinical outcomes, is largely unknown. By analyzing bulk RNA-seq data and scRNA-seq data, our results showed a direct correlation between RNF8 expression and immune cells such as monocytes and macrophages in various cancers. These findings might provide new insights into RNF8-regulated tumor-associated biological processes and mechanisms.

In summary, our identification of the RNF8 interactome revealed numerous new targets of RNF8. Based on these identified targets and integrated bioinformatic analysis, we systematically revealed the potential functions of RNF8 at the protein–protein interaction level and pathway levels. We believe our work will provide a unique framework for researchers and clinicians who seek to better explore or understand RNF8-regulated biological functions, as well as their clinical applications.

Conclusion
In this study, we identified a reference map of the RNF8 interactome network containing many new targets, such as YBX1, DNMT1, and HDCA1, new biological functions and the gene-disease associations of RNF8. We also revealed the unrecognized relationship between RNF8 and neurodegenerative diseases or tumor-infiltrating immune cells, and validated the direct binding between RNF8 and YBX1, and showed that RNF8 catalyzed the ubiquitination of YBX1, showing that RNF8 might be a crucial regulator of YBX1. Our work provides a unique framework for researchers and clinicians who seek to better explore or understand RNF8-regulated biological functions in cancers and diseases. This study will hopefully facilitate the rational design and further development of anti-RNF8 therapy in cancers.

Methods
Evaluation of the prognostic value and methylation status of RNF8
The Visualization of RNF8 methylation status, RNF8 expression, and corresponding clinical data were performed by MEXPRESS (https://mexpress.be/) [43, 44], a user-friendly online tool showing the DNA methylation, expression, and clinical data for the selected genes. The precise genomic location of DNA methylation is one of the most important regulatory factors of gene expression is also shown in MEXPRESS [45]. The TIMER 2.0 database (http://timer.cistrome.org/) is a comprehensive resource for systematical analysis of immune infiltrates.
across diverse cancer types [40]. The Oncomine database (https://www.oncomine.org/) is a user-friendly online tool that provides integrated analysis using datasets composed of samples represented as microarray data measuring either mRNA expression or DNA copy number on primary tumors [46].

**Searching the potential RNF8-interacting proteins**

Genemania (https://genemania.org/) is an online tool that finds other related genes using association data include protein and genetic interactions, pathways, co-expression, co-localization, predictions, and protein domain similarity [47]. Search Tool for the Retrieval of Interacting Genes (STRING, https://string-db.org/) [48] is a dataset to predict protein–protein interactions including physical and functional associations, deriving from computational predictions, knowledge transfer between organisms. HitPredict (http://www.hitpredict.org/) [49], BioGRID (https://thebiogrid.org/) [50] and inBio_Discover [51] (https://inbio-discover.com/#home) were also used to find the potential RNF8-interacting proteins.

**Functional enrichment analysis**

ClusterProfiler, a user-friendly R package for gene annotation and analysis was utilized to make sense of one or multiple gene lists [22], for gene ontology (GO) annotation and enrichment analyses including KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway and WikiPathways. Adj. \( P < 0.05 \) was considered significant.

**Protein–protein interaction analysis**

The protein–protein interaction (PPI) network of overlapping genes was constructed by STRING [48] and Metascape [22]. In the present study, the default setting was set as the selection criterion of constructing the network, all disconnected nodes were excluded from the network. The list of PPI pairs was downloaded for further analysis and visualized by Cytoscape software (version 3.7.1). Molecular Complex Detection (MCODE) plugin in Cytoscape was utilized to find the potential cluster in the PPI network based on topology. The degree cut-off value to 2 and the node score cut-off to 0.2 were set in the MCODE process.

**Pan-cancer prognostic value of hub genes**

To assess the prognostic value of hub genes in pancancer dataset, Gene Expression Profiling Interactive Analysis (GEPIA) tool (http://geopia.cancer-pku.cn/), including integrated TCGA mRNA sequencing data and the GTEx, were also used (with FDR \( P \) value adjustment, 0.05 significance level, and Median group cut-off) to calculate patient overall survival rate (OS) and relapse-free survival rate (RFS) [52, 53]. The results were shown in form of a heatmap with colors of cells showing \( \log_{10}(HR) \) and the frame meaning significance.

**Integrated analysis of tumor-infiltrating immune cells**

Pancancer-normalized mRNA expression dataset \((n = 11,060)\) and curated clinical data \((n = 12,591)\) were downloaded from UCSC Xena Pan-Cancer Atlas Hub (https://pancanatlas.xenahubs.net). The samples in each cancer were analyzed separately. Samples were trisected based on RNF8 expression and divided into three group. Differential gene expression analysis was performed between RNF8 high-expression group and low-expression group. Subsequent Over-representation analysis and functional analysis including GO MF, GO BP, GO CC, HALLMARK, Reactome, Wikipathways and disease association analysis were performed using R package clusterProfiler (Ver. 4.2.1), DOSE, enrichplot and msigdb. Identified terms with significant \((P \) value < 0.05) were visualized by ggplot2.

For immune infiltrating analysis, six immune cell infiltration algorithms including Cibersort, xCell, EPIC, MCP-counter, quanTisq, TIMER were utilized to calculate the immune cells-infiltration score in pancancer dataset using R package USCSXenaShiny [54]. Scores of different immune cells were clustered and visualized as heatmap using ggplot2.

**scRNA-seq data analysis**

Ten single cell transcriptome (GSM) data were analyzed using R package Seurat. After filtering cells \((\text{nFeature}_\text{RNA} \geq 200 \& \text{nFeature}_\text{RNA} \leq 2500 \& \text{percent.mt} < 20)\), expression data were normalized and scaled using “Log-Normalize” method and function “ScaleData”. Uniform Manifold Approximation and Projection (UMAP) and tSNE was used for dimension reduction. With cells labelled by metadata downloaded from GEO167087. The mean expression of RNF8 in nontumorous cells were calculated as:

\[
\text{Exp}_{\text{RNF8}} = \frac{\sum_{1}^{\text{nontumorous}} \text{n}_i \text{Exp}_{\text{RNF8}i}}{\text{n}_\text{All cells} - \text{n}_\text{cancer cells}}
\]

While \(\text{n}_{\text{nontumorous}} = \text{n}_\text{All cells} - \text{n}_\text{cancer cells}\). Besides, the percentage of a certain type \((\text{type} x)\) of immune cells were calculated with following formula:

\[
\text{P}_{\text{tumor infiltrating immune cells} x} = \frac{\text{n}_x}{\text{n}_\text{nontumorous}}
\]
**In vitro proof of concept for bioinformatic analyses**

**Cell culture**
Human embryonic kidney cell line 293T were purchased from American Type Culture Collection (ATCC, Manassas, VA), and cultured in RPMI 1640 Medium (Hyclone) supplemented with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA) and 100 U/ml penicillin and streptomycin (P/S; Hyclone). Cells were contained in a 5% CO$_2$ incubator at 37 °C.

**Co-immunoprecipitation**
For exogenous Co-IP, HEK293T or MCF7 cells were transfected with corresponding plasmid, after 48 h, adapted to suspension conditions and lysed in NETEN buffer (150 mmol/L NaCl, 20 mmol/L Tris – HCl (pH 7.40), 0.1% Nonidet P-40, 0.5 mmol/L EDTA, 1.5 mmol/L MgCl2, 10% glycerol) containing phospho-Stop, and protease inhibitor cocktail. The supernatants were incubated with anti-Flag-M2-Agarose beads (Sigma) or anti-HA beads (Sigma) for 2–4 h at 4°C. Besides, endogenous Co-IP was performed using MCF7 cells with anti-RNF8 antibodies or normal-mouse IgG, and the bound proteins were analyzed via immunoblotting. About the Ubiquitination assay, as the Co-IP described above, HEK293T cells were transfected with the corresponding plasmid and performed with Flag-IP, the elution was analyzed via western blotting, anti-Myc antibody, anti-YBX1 antibody, and RNF8 antibody were used to detect the Ubiquitin-YBX1, YBX1, and RNF8 protein expression level respectively.

**Western blotting**
Total proteins of cells were extracted using RIPA lysis buffer (Beyotime) with Protease Inhibitor (Roche) and Phosphatase Inhibitor (Roche). Protein samples were separated in sodium dodecyl sulfate (SDS)-PAGE and transferred to polyvinylidene fluoride (PVDF) filter membranes (Millipore, USA) for immunoblotting. After 1 h of blocking in PBST (phosphate buffer saline containing 0.05% Tween-20 and 5% non-fat milk powder), the membranes were incubated with one of the following primary antibodies with corresponding concentration: RNF8 (Santa Cruz Biotech, 1:500), YBX1 (Cell Signaling Technology, 1:1000), HA (Convance, 1:1000), Secondary antibodies were Horseradish peroxidase (HRP)-conjugated anti-mouse IgG (ZB-2305, ZSGB-Bio, 1:4000) or anti-Rabbit IgG(Fc) (ZB-2301, ZSGB-Bio, 1:4000). Subsequently, band visualization was performed by electrochemiluminescence (ECL) and detected by Digit imaging system (Thermo, Japan), the gray level of the bands was quantitated by Image) software.

**Statistical analysis**
Statistical analysis was conducted using the GraphPad Prism. All results were presented as the mean ± standard error of the mean (SEM). $P$ values are indicated in the text and figures above the two groups compared and $P<0.05$ (denoted by asterisks) was considered as statistically significant.

**Abbreviations**
GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; TCGA: The Cancer Genome Atlas Project; GEO: Gene Expression Omnibus; LUAD: Lung adenocarcinoma; EMT: Epithelial–mesenchymal transition; STRING: The Search Tool for the Retrieval of Interacting Genes; PPI: Protein–protein interaction; GEPIA: Gene Expression Profiling Interactive Analysis; GTEx: Genotype-Tissue Expression; MFs: Molecular functions; BPs: Biological process; CCs: Cellular compounds.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s13062-022-00331-z.
Additional file 15. Table S1. 218 proteins identified by intersection of two dataset.

Additional file 16. Table S2. Hub genes list identified from online tools and LC-MS-based identification.

Acknowledgements

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest. All the authors have read and approved the final manuscript.

Funding

This work was supported by a grant from the National Natural Science Foundation of China (No. 31870855 and No. 31900537), the National Science Foundation of Hunan Province, China (No. 2019J50731) and the National University of Defense Technology project (No. ZK21-48).

Availability of data and materials

All the data and materials supporting the conclusions are included in the main paper and additional materials.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All the authors have read and approved the paper and declare no potential conflicts of interest in the paper.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests.

Author details

1 Department of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha 410073, Hunan, China.
2 Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou 311121, Zhejiang, China.
3 Joint Logistic Support Force 92th Hospital, Changsha 410073, Hunan, China.
4 Department of Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.

Received: 14 March 2022 Accepted: 20 June 2022

Published online: 13 July 2022

References

1. Nazari M, Babakhanzadeh E, Zarch SMA, Talebi M, Narimani N, Dargahi M, et al. Upregulation of the RNF8 gene can predict the presence of sperm in azoospermic individuals. Clin Exp Reprod Med. 2020;47(1):61–7.
2. Kuang J, Min L, Liu C, Chen S, Gao C, Ma J, et al. RNF8 promotes epithelial–mesenchymal transition in lung cancer cells via downregulation of Twist1. Cell Death Differ. 2019;26(2):306–20.
3. Liu C, Min L, Kuang J, Zhu C, Qu X-Y, Zhu L. Bioinformatic identification of miR-622 key target genes and experimental validation of the miR-622-RNF8 axis in breast cancer. Front Oncol. 2019;9:1114.
4. Min L, Liu C, Kuang J, Wu X, Zhu L. miR-214 inhibits epithelial–mesenchymal transition of breast cancer cells via downregulation of RNF8. Acta Bioch Biophys Sin. 2019;51(8):791–8.
5. Xie H, Hu Y, Xu T, Yan K, Zhang T, Li Q, et al. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell reports. 2021;37:109854. https://doi.org/10.1016/j.celrep.2021.109854.
6. Zhao M-J, Song Y-F, Niu H-T, Tian Y-X, Yang X-G, Xie K, et al. Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy. Oncotarget. 2016;7(8):8956–67.
28. Zhou H, Mu X, Chen J, Liu H, Shi W, Xing E, et al. RNAi silencing targeting RNF8 enhances radiosensitivity of a non-small cell lung cancer cell line A549. Int J Radiat Biol. 2015;89(9):708–15.

29. Valnegri P, Huang J, Yamada T, Yang Y, Mejia LA, Cho HY, et al. RNF8/UBC13 ubiquitin signaling suppresses synapse formation in the mammalian brain. Nat Commun. 2017;8(1):1271.

30. Suresh PS, Tsutsumi R, Venkatesh T. YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts. Nucleic Acids Res. 2012;40(7):8622–36.

31. Wei WJ, Mu SR, Heiner M, Fu X, Cao LJ, Gong XF, et al. YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts. Nucleic Acids Res. 2012;40(7):8622–36.

32. Sanna S, Esposito S, Masala A, Sini P, Nieddu G, Galioto M, et al. HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo. Cell Death Dis. 2020;11(5):369.

33. Ouyang S, Song Y, Tian Y, Chen Y, Yu X, Wang D. RNF8 deficiency results in neurodegeneration in mice. Neurobiol Aging. 2015;36(10):2850–60.

34. Kolas NK, Chapman JR, Nakada S, Ylaniko J, Chahwan R, Sweeney FD, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science. 2007;318(5856):1637–40.

35. Wang S, Xiong Y, Zhao L, Gu K, Li Y, Zhao F, et al. RNFL Transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein phosphorylation. Cell. 2007;131(5):901–14.

36. Chen H, Shang J, Liu J, Feng Y, Zeng X. RNF8 promotes efficient DSB repair by inhibiting the pro-apoptotic activity of p53 through regulating the function of Tip60. Cell Prolif. 2020;53(4):e12780.

37. Mao Y, Zhang Q, Qin X, Li J, Liu J, et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20(12):1425–33.

38. Wang S, Luo H, Wang C, Sun H, Sun Q, SUN N, et al. RNF8 Identified as a co-activator of estrogen receptor α promotes cell growth in breast cancer. Biochim Biophys Acta Mol Basis Dis. 2017;1863(6):1615–28.

39. Koch A, Diedrich JH, et al. DNA damage-induced histone H1 ubiquitylation is mediated by HUWE1 and stimulates the RNF8-RNF168 pathway. Sci Rep. 2017;7(1):15353.

40. Liu J, Chen J, Liu H, Shi W, Xing E, et al. RNAi silencing targeting RNF8 enhances radiosensitivity of a non-small cell lung cancer cell line A549. Int J Radiat Biol. 2015;89(9):708–15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.